During the last session, Dianthus Therapeutics Inc (NASDAQ:DNTH)’s traded shares were 0.37 million, with the beta value of the company hitting 1.85. At the end of the trading day, the stock’s price was $27.50, reflecting an intraday loss of -2.90% or -$0.82. The 52-week high for the DNTH share is $33.77, that puts it down -22.8 from that peak though still a striking 76.07% gain since the share price plummeted to a 52-week low of $6.58. The company’s market capitalization is $807.68M, and the average intraday trading volume over the past 10 days was 0.27 million shares, and the average trade volume was 201.83K shares over the past three months.

Dianthus Therapeutics Inc (DNTH) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.20. DNTH has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.59.

Dianthus Therapeutics Inc (NASDAQ:DNTH) trade information

Dianthus Therapeutics Inc (DNTH) registered a -2.90% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.90% in intraday trading to $27.50, hitting a weekly high. The stock’s 5-day price performance is -1.79%, and it has moved by -1.11% in 30 days. Based on these gigs, the overall price performance for the year is 123.03%. The short interest in Dianthus Therapeutics Inc (NASDAQ:DNTH) is 4.97 million shares and it means that shorts have 25.83 day(s) to cover.

The consensus price target of analysts on Wall Street is $51, which implies an increase of 46.08% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $51 and $51 respectively. As a result, DNTH is trading at a discount of -85.45% off the target high and -85.45% off the low.

Dianthus Therapeutics Inc (DNTH) estimates and forecasts

Statistics show that Dianthus Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Dianthus Therapeutics Inc (DNTH) shares have gone up 6.22% during the last six months, with a year-to-date growth rate more than the industry average at 73.02% against 17.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 84.40% this quarter and then jump 8.50% in the quarter after that. In the rating firms’ projections, revenue will increase 42.30% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 650k as predicted by 8 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to 650k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 924k and 457k respectively. In this case, analysts expect current quarter sales to shrink by -29.70% and then jump by 42.20% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 29.95%. While earnings are projected to return 73.82% in 2024.

DNTH Dividends

Dianthus Therapeutics Inc is due to release its next quarterly earnings on 2024-Nov-07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Dianthus Therapeutics Inc (NASDAQ:DNTH)’s Major holders

Dianthus Therapeutics Inc insiders own 8.83% of total outstanding shares while institutional holders control 101.69%, with the float percentage being 111.54%.